Member Societies

• All
• 298
• 299
• 300

The 5th Joint Session between KDDW-TDDW-JDDW (Upper GI) : Novel Diagnostic and Therapeutic Approaches to Upper GI Motility Disorders English

Date / Time	298,
Channel
Speakers	08:30-08:50	Usefulness of high-resolution manometry for the management of oropharyngeal dysphagia
	08:50-09:10	Functional dyspepsia -Diagnosis and treatment-
	09:10-09:30	Esophageal mucosal histopathology may help differentiate achalasia from refractory gastroesophageal reflux disease
	09:30-09:40	New parameter for quantifying bolus transit with high-resolution impedance manometry
	09:40-09:50	Assessment of esophagogastric junction in post-POEM reflux esophagitis
	09:50-10:00	Comparison of manometric diagnosis by Chicago classification version 3.0 and 4.0 on esophageal high resolution manometry

The 5th Joint Session between KDDW-TDDW-JDDW (Lower GI) : Optimal Management of IBD in the Biologics Era English

Date / Time	298,
Channel
Speakers	10:15-10:35	Early intervention in IBD: Why and how?
	10:35-10:55	Deep neural network for colonoscopy of ulcerative colitis
	10:55-11:15	Transmural healing: The dream or the ideal to be achieved
	11:15-11:25	Big data research: Progress makes practice in IBD
	11:25-11:35	The role of endoscopy in inflammatory bowel disease
	11:35-11:45	Clostridium innocuum in inflammatory bowel disease

The 5th Joint Session between KDDW-TDDW-JDDW (Pancreatobiliary) : The Strategies for Resectable/borderline-resectable Pancreatic Cancer English

Date / Time	298,
Channel
Speakers	12:25-12:45	Upfront surgery for resectable/borderline-resectable pancreatic cancer
	12:45-13:05	Neoadjuvant therapy for resectable/borderline-resectable pancreatic ductal adenocarcinoma
	13:05-13:25	Should we perform neoadjuvant therapy in resectable pancreatic cancer?
	13:25-13:35	Neoadjuvant chemotherapy for resectable/borderline-resectable pancreatic cancer
	13:35-13:45	The strategies for resectable / borderline-resectable pancreatic cancer
	13:45-13:55	Reshaping resectable/borderline-resectable pancreatic cancer in the era of precision medicine

The 5th Joint Session between KDDW-TDDW-JDDW (Liver) : Strategies for Elimination of Chronic HBV Infection: Current Status and Future Perspectives English

Date / Time	298,
Channel
Speakers	14:10-14:30	Optimize nucleot(s)ide analogues’ to prevent hepatocellular carcinoma in patients with chronic hepatitis B: A lesson from real-world evidence
	14:30-14:50	Current status in hepatitis B management in Japan and future perspectives
	14:50-15:10	Towards Elimination of HBV Infection in Taiwan
	15:10-15:20	Identifying hepatocellular carcinoma risk of untreated chronic hepatitis B for timely antiviral intervention
	15:20-15:30	Role of host immune responses in achieving HBsAg loss
	15:30-15:40	Combined ALT/HBsAg kinetics for re-treatment decision in HBeAg-negative CHB patients with off-Nuc hepatitis flare